Business Update and Notice of Results

AI SummaryClose X

Thalia Therapeutics plc has provided a business update detailing progress across its oncology, cardiovascular, and RNA delivery programmes, alongside a notice of its interim results for the six months ended 30 June 2026, due on 30 September 2026. The company has completed its strategic transformation into a clinical-stage RNA therapeutics firm following the acquisition of Sanmirna Therapeutics Inc. and a £2.75 million fundraise. Its Phase 1 trial for THAT-001 (miRisten) in Acute Myeloid Leukaemia is on schedule with top-line data expected in H1 2027, while preclinical development has commenced for THAT-002, a bispecific siRNA cardiovascular programme targeting PCSK9 and Lp(a). Furthermore, ex-vivo studies are underway for the Nuvec® RNA delivery platform to demonstrate targeted liver delivery. Luke Cairns has been appointed Chief Financial Officer.

Disclaimer*

UK 100

Latest directors dealings